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The demonstration of activated T lymphocytes and HLA-DR' keratinocytes in
psoriatic plaques suggests that delayed cellular immune responses may play an im-
portant role in the pathogenesis of psoriasis (1-3). -y-Interferon (IFN-y) is an impor-
tant cytokine, produced by activated T lymphocytes, which elicits many features
of delayed cellular immune responses in vivo. These include induration, mononuclear
cell infiltration, keratinocyte proliferation, Langerhans cell redistribution, and in-
duction of keratinocyte HLA-DR expression (4). Additionally, IFN-y induces ker-
atinocyte HLA-DR expression in vitro (5). IP-10 is a cytokine the expression ofwhich,
in keratinocytes and other cells, is induced by IFN-y (6, 7). It is structurally homol-
ogous to a family of proteins with chemotactic and mitogenic activities (8). IP-10
has been detected during the development of cutaneous delayed cellular immune
responses (9). To further study the role ofthese reactions in the pathogenesis ofpsoriasis,
active plaques were tested for the presence of the IP-10 protein. We now report that
IP-10 was detected in keratinocytes from active psoriatic plaques.
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Material and Methods
Patients and Skin Biopsies.
￿
Biopsies of normal skin and of lesional and normal-appearing
skin from 34 patients with psoriasis vulgaris, 2 patients with erythrodermic psoriasis, and
1 patient with pustular psoriasis of the von Zumbusch type were taken afterinformed consent
was obtained in accordance with a protocol approved by the Rockefeller University Hospital
Institutional Review Board. 16 patients received treatment with topical tar and ultraviolet
B irradiation, 1 received etretinate (Hoffman-La Roche, Nutley, NJ) and 1 received topical
corticosteroids. Treatment continued for 3-4 wk, with marked clinical improvement in scale,
erythema, and thickness, before obtaining repeat biopsies (1).
Immunoperoxidase Studies.
￿
Immunoperoxidase studies offormalin-fixed frozen skin sections
with an affinity-purified rabbit anti-IP-10 antibody (7) were performed as previously described
(1). Absorption experiments were performed by incubating the anti-IP-10 antibody with gel-
purified recombinant IP-10 protein coupled to CNBr-activated Sepharose 4 B (Pharmacia
Fine Chemicals, Piscataway, NJ) (7) overnight at 4°C. For competition experiments, the anti-
IP-10 antibody was mixed with soluble IP-10 protein or an equal volume of phosphate buffered
saline (PBS) just before incubation with the skin sections.
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RNA Isolation and Northern Blotting.
￿
Skin biopsies were snap frozen in liquid nitrogen and
stored at -70°C . Total cellular RNA was isolated from these biopsies by the guanidinium
isothiocyante-cesium chloride method (10) . 4-ug samples ofRNA per biopsy specimen were
fractionated on a 1% agarose gel containing 2.2 M formaldehyde, transferred to nitrocellu-
lose, and hybridized with a 32p-labeled 355 by FNU4H1 fragment of the IP-10 cDNA pIFN-
y31.7 containing only coding sequence (6) . The y-actin cDNA was a generous gift from Dr.
Larry Kedes, Stanford University, Stanford, CA (11) .
Immunoprecipitation Analysis .
￿
Cultured normal human keratinocytes were grown in serum-
free low-calcium medium as previously described (12) . 500 PCi of35[S]methionine (New En-
gland Nuclear, Boston, MA) were added to each 75-cm2 flask containing a confluent
monolayer of keratinocytes, and 10 ml of methionine-free RPMI-1640 (Flow Laboratories,
Inc., McLean, VA .) plus 10% dialyzedFCS (Hyclone Laboratories, Inc., Logan, UT) . Human
IFN-y (100 Ulml), purified from peripheral blood buffy-coat white blood cells (13), was added
to selected flasks. All flasks were incubated overnight at 37°C in 5% C02 . The superna-
tants were aspirated and saved . After three washes in PBS, the cells were lysed with 0.5%
NP-40 plus 100mM iodoacetamide, and immunoprecipitations performed as described (14) .
Results
As previously described (7), antibody to IP-10 immunoprecipitates a 6-10 kDband
from 35S-labeled normal keratinocytes (Fig. 1) . This molecule can be identifed both
in cell lysates of labeled keratinocytes and in cell supernatants provided these cells
are exposed to IFN-y . Thus, IP-10 is an IFN-y inducible protein produced by normal
keratinocytes .
Keratinocytes in active plaques from 37 patients were reactive with the anti-IP-10
antibody by immunoperoxidase staining (Fig. 2 a) . The pattern ofstaining was cyto-
plasmic and basal keratinocytes were more intensely stained than were spinous ker-
atinocytes . Varying percentages of cells in the dermal infiltrate were stained, but
in all cases stainingwas less intense than that of the keratinocytes . This observation
is consistent with quantitative immunoprecipitation studies, which demonstrated
greater IFN-y-induced IP-10 synthesis in keratinocytes as compared with monocytes,
FIGURE 1 .
￿
Keratinocytes cultured in confluent monolayers were
metabolically labeled with 35[S]methionine . Cell lysates and cell
supernatants were immunoprecipitated with antibody to IP-10 . A
specific band of ti10 kD was immunoprecipitated when keratino-





Immunoperoxidase reactivity oflesional and unin-
volved skin from a psoriasis patient with the anti-IP-10 anti-
body. 190 . (a) Plaque before treatment shows cytoplasmic
staining ofmost ofthe keratinocytes. (b) Uninvolved skin from
thesame patient demonstrated staining ofonly the basal layer.
(c) After 3-4 wk of topical tarand ultraviolet B therapy, only
the basal epidermal layer of the plaque reacted with the anti-
IP-10 antibody.
endothelial cells, and fibroblasts(9) . Normal-appearing skin, taken from 20 ofthese
psoriatic subjects before treatment, demonstrated staining of only the basal layer
(Fig . 2 b) . In this respect, unaffected skin from psoriasis patients stained identically
to skin from normal individuals.
In contrast with pretreatment plaques, only the basal epidermal layer of treated
plaques reacted with the anti-IP-10 antibody in most cases (Fig . 2 c) . After 3-4 wk of
therapy, all patients experiencedmarked improvement in clinical scaling, erythema, and
thickness . Routine microscopy demonstrated significant reductions in epidermal acan-
thosis . As reported previously, treated psoriatic plaques had essentially no HLA-DR'
keratinocytes (1) and significantly fewer T lymphocytes bearing IL-2 receptors (1,
15) suggesting that treatment dampens the ongoing cellular immune response .
To confirm that staining with the anti-IP-10 antibody was specific, both absorption944
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FIGURE 3 .
￿
Absorption with IP-10 inhibits binding of the anti-IP-10 antibody to skin . x 190 . Ab-
sorption with recombinant IP-10 removed reactivity of the anti IP-10 antibody with an active
psoriatic plaque (b) anduninvolved skin (d) . Reactivity of untreated antibody with thesame ac-
tive plaque and uninvolved skin is shown in (a) and (c), respectively .
and competition experiments were performed . Absorption with recombinant IP-10
protein removed all staining by the anti-IP-10 antibody ofboth psoriatic and nonle-
sional keratinocytes (Fig . 3) . Theseobservations were confirmed by competition ex-
periments in which soluble IP-10 protein was added to the anti-IP-10 antibody just
before incubation with the skin sections . IP-10 protein, but not an equal volume
of PBS, removed reactivity ofthe antibody with both psoriaticand normal keratino-
cytes (data not shown) .
Northern blot analysiswas performed to determine if theincrease in IP-10 staining
is psoriatic plaques was associated with an increase in the steady-state level of the
IP-10mRNA . Total cellular RNA was isolated from patients' active ps'oriatic plaques,
as well as from their normal-appearing skin . Identical amounts ofRNA were sub-
jects toRNA blot analysis using the IP-10 cDNA probe (Fig . 4) . IP-10mRNA was
found in theRNA isolated from active plaques but was not detected in uninvolved
skin from the same patients . When the identical blot was reacted again using ay-actin
cDNA probe, therewere similar levels ofactinmRNA present in both active plaques
and nonlesional skin . Similar results were obtained with biopsies of plaques and
normal-appearing skin from three other patients . These findings suggest that the
observed increase in IP-10mRNA in lesional psoriatic skin could not be explained
on the basis of a nonspecific increase in total mRNA content, and is instead the





Northern blot analysis oflesional and nonlesional skin from
a psoriasis patient . Total cellularRNAwas isolated from an active psori-
atic plaque andfrom normal appearing skin from thesame patient . Iden-
tical amounts of RNA were subjected to RNA blotting analysis using
the IP-10 cDNA probe and a y-actin cDNA probe . IP-10 mRNA was
found in the RNA isolated from the active plaque (Plaque) but was not
detected in uninvolved skin from thesame patient (Normal) . Similar levels
of actin mRNA were present in both the plaque and nonlesional skin
as can be seen when the identical blot was rehybridized with a y-actin
cDNA probe .
Discussion
IP-10, a cytokine the expression of which is induced by IFN-y, is a member of
a newly emerging family of soluble mediators, including chemotactic and platelet-
granule proteins (platelet factor 4, R thromboglobulin, connective tissue-activating
peptide III), proteins induced by transformation (9E3 and gro), proteins induced
by growth factors (310c and KC), and known growth factors(melanocyte-stimulating
factor and connective tissue-activating peptide III) (reviewed in 7, 8, 16) . These
proteins have chemotactic andmitogenic activities and are involved in inflammation
and growth control.
IP-10 was detected in keratinocytes from active psoriatic plaques . Successful treat-
ment ofplaques by various meansdecreasedexpression of IP-10 in plaques. Activated
T cells andHLA-DR' keratinocytes have been detected in active psoriatic plaques
(1-3) . Since IP-10 is detected in delayed cellular immune responses (9), the present
study further points to the role ofongoing cellular immune responses in the patho-
genesis of psoriasis .
Based upon its structural homology to a number of proteins with chemotactic and
growth promoting activities, one can speculate that IP-10 may have similar functions
that play a role in the pathogenesis of psoriatic plaques . For instance, IP-10 may be
a chemotactic stimulus for the neutrophils, monocytes andT lymphocytes that are
abundant in active plaques . In addition, IP-10 might promote keratinocyte growth and
be responsible in part for the keratinocyte hyperproliferation seen in psoriatic plaques.
IFN-1'-induced increases in IP-10 synthesis may, in part, be responsible forthe flaring
of psoriasis that is associated with a number of conditions, e.g . streptococcal infec-
tion, reaction to certain drugs, and the acquired immunodeficiency syndrome .
Theimmunocytochemical detection of IP-10 in normal basal keratinocytes suggests
that it plays a role in normal growth regulation . However, IP-10 mRNA is not de-
tected in nonlesional skin . Additionally, IP-10 protein is not immunoprecipitated946
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from cultured normal human keratinocytes in the absence of IFN-y, despite the fact
that these cells are stained by the same antibody in immunoperoxidase studies (data
not shown) . Thus, the anti-IP-10 antibody may react with a crossreactive epitope
expressed in basal keratinocytes that is unrelated to IP-10 protein. Alternatively, IP-10
mRNA expression in normal skin may be below the limits of detection by Northern
blot analysis due to the limited expression of IP-10 in basal keratinocytes which make
up only a small fraction of the biopsy samples.
Soluble mediators of inflammation, such as IFN-y, produced in psoriatic lesions
and during delayed cellular immune responses, may generate activated keratinocytes.
We postulate that the principal functions of these cells are increased cell division,
secretion of cytokines, and increased motility. Cytokines could influence keratinocyte
growth in an autocrine manner, as has been described for IL-1 (17) and transforming
growth factor a (18, 19). Cytokines released from activated keratinocytes could also
promote growth and differentiation of neighboring epidermal cells, e.g., melano-
cytes, Langerhans cells, and Thy-l' dendritic cells. For instance, keratinocyte gran-
ulocyte/macrophage colony-stimulating factor (GM-CSF) increases Langerhans cell
differentiation in vitro (20, 21). Additionally, secretory products of keratinocytes such
as IL-1 (22-24) and IL-6 (25-27) could activate monocytes and T cells in the under-
lyingdermis. It is well known that increased keratinocyte motility is an integral part
of the wound-healing process. After wounding, basal keratinocytes migrate to the
injured area, and mitoses can be seen at the edge of the defect .
The active psoriatic plaque can be viewed as an aberrant local overproduction
of activated keratinocytes. Thus increased levels of cytokines, specifically IP-10 pro-
tein and arachidonic acid metabolites (28) have been detected in active plaques. Ker-
atinocyte HLA-DR expression has been demonstrated in psoriatic plaques as well
as in other inflammatory cutaneous lesions (reviewed in 1), and in the cutaneous
delayed-type hypersensitivity reaction to the purified protein derivative of tuberculin
(29). Psoriatic plaques also exhibit altered epidermal growth factor receptor expres-
sion (30), keratin expression (31), plasm]nogen-activator distribution (32), 4F2/EL-
2 expression (33), lectin reactivity (34), and increased protein kinase C activity (35).
Moreover, keratinocytes isolated from psoriatic plaques demonstrate increased RNA
content and increased numbers of cells within the S, Gz, and mitotic phases of the
cell cycle when compared with uninvolved skin from the same patients or skin from
normal individuals (33) .
Thus, the elucidation of how inflammation and keratinocyte growth are inter-
related has direct application to the understanding of a large number of inflamma-
tory and hyperproliferative cutaneous diseases .
Summary
The pathologic features of psoriatic plaques are inflammation and increased
epidermal turnover. IP-10, a cytokine the expression of which is induced by y-inter-
feron, is a member of a family of soluble mediators with inflammatory and growth-
promoting activities. IP-10 protein was detected in keratinocytes and the dermal in-
filtrate from active psoriatic plaques using an affinity-purified rabbit anti-IP-10 antibody
in immunoperoxidase studies. Successful treatment ofactive plaques decreased IP-10
expression in plaques. These results were corroborated by Northern blot analysis
with an IP-10 cDNA probe. We have previously detected activated T cells and HLA-DR' keratinocytes in active psoriatic plaques. Since IP-10 is detected in delayed cel-
lular immune responses, the present study further points to the role of ongoing cel-
lular immune responses in the pathogenesis of psoriasis .
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